Open Access

Atypical carcinoid: A rare finding of a man with mediastinal mass: A case report

  • Authors:
    • Wei‑Xia Xuan
    • Jin‑Jin Li
    • Yu‑Jie Shi
    • Xiao‑Ju Zhang
  • View Affiliations

  • Published online on: February 19, 2020     https://doi.org/10.3892/mco.2020.2001
  • Pages: 325-328
  • Copyright: © Xuan et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The present case report describes a case of mediastinal atypical carcinoid and a favorable outcome linked with the treatment. Mediastinal atypical carcinoid is a rare and aggressive type of neuroendocrine tumor. A 56‑year‑old man was admitted at the Respiratory Department due to intermittent tightness of the chest for 1 month. An initial diagnosis of a mass in the left anterior mediastinum was conducted using CT scan and immunohistochemistry. Laboratory data revealed the following values: Neuron Specific Enolase of 62.13 ng/ml (reference range, 0‑40 ng/ml); CYFRA21 of 3.01 ng/ml (reference range, 0‑3.3 ng/ml); CEA of 4.22 (0‑6.5) ng/ml; SCC of 0.5 (0‑1.5) ng/ml; CA125 of 67.24 (0‑35) U/ml; AFP of 23 (0‑25) U/ml; CRP of 96.7 (0‑10) mg/l; PCT <0.05 (0‑0.05) ng/ml; and ESR of 48 (0‑20) mm/h. Tissue pathology revealed tumor cells with small cell pattern, and cell proliferation activity was 10%. Combined chemotherapy with bevacizumab (0.4 g, qd, once every 21 days) and capecitabine (0.15 g, Bid, Po) and timozolamine (0.34 mg, qd, po) was administered for 6 cycles. After the patient was given chemotherapy, the symptoms and CT exhibited improvement. On March 11, 2018, the lesion progressed into the lymph and pleura. The patient was commenced on radiotherapy and new chemotherapeutic regimen etoposide (0.5 g)‑carboplatin (0.4 g)‑bevacate (0.4 g). Another CT scan was performed after a month which revealed a substantial decrease in tumor size. Hence, a CT scan was performed for this patient who further revealed a decrease in tumor size. Currently patients are treated with bevacizumab maintenance therapy. Further studies of conservative treatment of chemotherapy and radiotherapy may provide a treatment to improve atypical carcinoid.
View Figures
View References

Related Articles

Journal Cover

April-2020
Volume 12 Issue 4

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Xuan WX, Li JJ, Shi YJ and Zhang XJ: Atypical carcinoid: A rare finding of a man with mediastinal mass: A case report. Mol Clin Oncol 12: 325-328, 2020
APA
Xuan, W., Li, J., Shi, Y., & Zhang, X. (2020). Atypical carcinoid: A rare finding of a man with mediastinal mass: A case report. Molecular and Clinical Oncology, 12, 325-328. https://doi.org/10.3892/mco.2020.2001
MLA
Xuan, W., Li, J., Shi, Y., Zhang, X."Atypical carcinoid: A rare finding of a man with mediastinal mass: A case report". Molecular and Clinical Oncology 12.4 (2020): 325-328.
Chicago
Xuan, W., Li, J., Shi, Y., Zhang, X."Atypical carcinoid: A rare finding of a man with mediastinal mass: A case report". Molecular and Clinical Oncology 12, no. 4 (2020): 325-328. https://doi.org/10.3892/mco.2020.2001